It has been a pleasure working with Jon Preece, FRSC and his team to secure their funding. This is a ground-breaking technology that will really impact on the sector, delivering real benefits to the supply chain and the end consumer.
Chromatwist is developing novel patented tunable fluorescent dyes, for the high growth flow cytometry reagent market ($2.9Bn by 2027), with a focus on the premium UV dye sector. Flow cytometry is a diagnostic tool which analyses cells characteristics and is used in diagnostics, drug discovery, vaccine development, cancer research, and immunology, to name but a few. ChromaTwist’s patented dyes have unique light absorbing and tunable light emitting properties which are being developed in their laboratories to significantly enhance the capability of flow cytometry.
Jon Preece, FRSC, CEO said, “I cannot praise the angelgroups approach enough for bringing early-stage companies together with potential investors. Martin Avison added value every step of the way: from the advice on our initial pitch deck, to the discussions with the investors after the pitch, right through to negotiations and completion of the investment with a very engaged group of Angels. I recommend Martin and angelgroups without reservation to any start-up, with an innovative technology, who are looking for a real value-added experience in the quest for investment in their product or service.”
We wish them every success in the future and are expecting great things.
